PI3K inhibitors as potential therapeutics for autoimmune disease by Ball, Jennifer et al.
        
Citation for published version:
Ball, J, Archer, S & Ward, S 2014, 'PI3K inhibitors as potential therapeutics for autoimmune disease', Drug
Discovery Today, vol. 19, no. 8, pp. 1195-1199. https://doi.org/10.1016/j.drudis.2014.04.002
DOI:
10.1016/j.drudis.2014.04.002
Publication date:
2014
Document Version
Peer reviewed version
Link to publication
Publisher Rights
CC BY-NC-ND
Published online via: http://dx.doi.org/10.1016/j.drudis.2014.04.002
University of Bath
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 13. May. 2019
 1 
 
PI3K Inhibitors As Potential Therapeutics for Autoimmune Disease 
 
Jennifer Ball*, Sophie Archer* and Stephen Ward 
Department of Pharmacy & Pharmacology, University of Bath, Claverton 
Down, BA2 7AY, UK 
 
 
 
 
Corresponding Author: 
Stephen Ward 
Department of Pharmacy & Pharmacology,  
University of Bath,  
Claverton Down,  
BA2 7AY, UK 
S.G.Ward @bath.ac.uk 
Tel: 01225 383641 
 
* These authors contributed equally to this work  
 
 
 
 
 
 
 
 
 
 
 
 
 
 2 
 
 
 
 
Abstract: 
Aberrant over-activation of the immune system can give rise to chronic and 
persistent self-attack, culminating in autoimmune disease. This is currently 
managed therapeutically using potent immunosuppression and anti-
inflammatories.  Phosphoinositide 3-kinase (PI3K) has been identified as an 
ideal therapeutic target for autoimmune diseases given its wide ranging roles 
in immunological processes. Recent studies into the function of selective PI3K 
inhibitors both in vitro and in vivo have yielded encouraging results, allowing 
progression into the clinic. Here we review their recent progress across a 
range of autoimmune diseases.  
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Introduction: 
Autoimmune diseases arise through aberrant activation of T and B 
lymphocytes towards self-derived antigen, a response normally prevented by 
immunological tolerance [1,2]. Drug therapy for autoimmune disease was 
revolutionised with the introduction of biological agents targeting TNF (e.g 
infliximab) and more recently T lymphocytes (e.g. abatacept) and B 
lymphocytes (e.g. rituximab). These provide powerful immunosuppression 
and have surpassed the clinical efficacy of classic disease modify anti-
rheumatic drugs (DMARDs) [3]. However, the concern over adverse effects 
and high cost often limits the early prescription of biological agent.  
Furthermore, not all patients are responsive to biological therapy and 
effectiveness is unpredictable. Finally, biological treatment has not been 
shown to induce a drug-free remission so continuous treatment is required for 
therapeutic benefit [4]. Together with the expanding emergence of 
autoimmune disease in an increasing worldwide population, these factors 
underline the need for simpler, cost effective small molecule therapeutics. 
Here, we discuss the evidence that targeting of phosphoinositide 3-kinase 
(PI3K) with small molecule inhibitors could provide an effective, safe 
treatment for the control of autoimmune diseases including rheumatoid 
arthritis (RA), multiple sclerosis (MS), systemic lupus erythematous (SLE) and 
autoimmune diabetes. 
 
Phosphoinositide 3-Kinase Signalling: 
Class I PI3K enzymes phosphorylate the D3 position on the inositol ring of 
phosphatidylinositol 4,5-bisphosphate [PI(4,5)P2] to generate PI(3,4,5)P3 
which controls a crucial signaling cascade implicated in a plethora of cellular 
responses (Figure 1).  The class I PI3K isoforms are composed of a p110 
kDa catalytic subunit and a tightly associated regulatory subunit (Figure 1). 
The three class IA p110 catalytic isoforms PI3Kα, PI3Kβ and PI3Kδ are 
activated downstream of a variety of receptors that are phosphorylated by 
tyrosine kinases upon cognate stimulus. The class IB catalytic isoform PI3Kγ 
is activated by G-protein βγ subunits and signals downstream of G protein-
coupled receptors (GPCRs) [5,6].  However recent evidence has suggested 
there may be greater diversity in receptor coupling to PI3K isoforms than 
originally thought, with PI3K also being coupled to GPCRs and PI3Kγ being 
coupled to tyrosine kinase-coupled receptors [7,8]. PI3Kα and PI3Kβ have a 
broad tissue distribution, while PI3Kδ and PI3Kγ are predominantly expressed 
in leukocytes, but can be found in some cancer cells of non-leukocyte origin 
[5].  
 
PI3K can be activated by a diverse array of receptors expressed on 
leukocytes responsible for both innate (neutrophils, macrophages) and 
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adaptive (T and B lymphocytes) immune responses as well as those that 
constitute a link (mast cells, eosinophils) between these two arms of the 
immune response. Mice in which the genes encoding PI3Kγ or PI3Kδ have 
been either ablated or altered to encode kinase-inactive mutants are viable, 
fertile and apparently healthy. However, when their immune system is 
challenged, they exhibit severely altered phenotypes demonstrating that 
PI3Kγ and PI3Kδ have non-redundant functions in leukocytes, and that the 
activities of these isoforms in immune cells are crucial during chronic 
inflammatory diseases [5]. Often these roles are quite distinct, requiring 
coordinated function of both isoforms at discrete steps of immune cell 
activation.  Although PI3K dependent signalling has been identified as critical 
for immune function, aberrant overactive PI3K signalling is known to result in 
immune-related pathologies [9, 10,11] providing substantial evidence that the 
inhibition of PI3K could provide a novel method of treating autoimmune 
disease.  
 
PI3K as a Pharmacological Target: 
The first compounds identified to block PI3K, the natural product wortmannin 
and Eli Lilly’s LY294002, have served as useful experimental tools with which 
to explore the PI3K pathway [10].  X-ray crystallography data of PI3Kγ bound 
to wortmannin and LY294002 helped to understand how these compounds fit 
into the ATP binding pocket [12] which in turn influenced attempts to design 
better compounds with increased potency and required selectivity.  
Furthermore mTOR shares high sequence homology within the ATP-binding 
pocket with PI3K and compounds originally developed as PI3K inhibitors were 
later shown to also target mTOR.  Pan-PI3K and mTOR inhibitors are under 
current investigation for the treatment of cancers where the PI3K/Akt/mTOR 
pathway is central to the transformed phenotype of most cancer cells [10].  
 
Due to the their largely restricted expression to hematopoietic cells, the 
impact of pharmacological targeting of PI3Kγ and PI3Kδ should be largely 
restricted to the immune system. Given the high degree of similarity that 
exists between the amino acids forming the ATP-binding pockets of the four 
class I PI3Ks, it was expected that isoform-selective inhibitors with a 
reasonable difference in potency would be difficult to obtain. However, the 
discovery of the quinazolinone purine series, exemplified by the ICOS 
compound IC-87114 indicated that this task was possible [10]. IC-87114 
demonstrated an IC50 value of approximately 100 nM for PI3Kδ lipid kinase 
activity while having negligible potency against the PI3Kα and PI3Kβ 
isoforms.  In 2006 several members of ICOS Corporation formed a spin-out 
company, Calistoga Pharmaceuticals. Calistoga developed CAL-101, a PI3Kδ 
specific inhibitor, which has experienced successful proof of concept in clinical 
trials for treatment of B cell malignancies  (13-16). This compound (recently 
renamed GS-1101) exhibits 40-300 fold selectivity over other PI3K isoforms 
(Figure 2).  In addition, patents describing PI3Kδ inhibitors have been filed by 
several other companies and the majorities are based on the same basic 
pharmacophore identified by ICOS [10]. 
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Selective inhibition of PI3Kγ has been accomplished in a series of compounds 
designed by Merck Serono SA based on the thiazolidinedione scaffold. One of 
these, AS-605240, has demonstrated superior potency for PI3Kγ compared to 
related compounds.  In general terms, the level of selectivity of compounds 
against PI3Kγ versus other PI3K isoforms has been largely disappointing.  
However, using a chemoproteomics-based drug discovery platform, 
researchers at Cellzome have designed CZC24832 which exhibits superior 
selectivity for PI3Kγ than previously reported compounds [10, 17].  
 
Given the evidence from gene-targeted mice that PI3Kγ and PI3Kδ often work 
in concert and can have overlapping roles, dual inhibition of both targets with 
a single compound has been considered. TargeGen described two 
diaminopteridine-diphenol-based compounds (TG-101-110, TG-100-115) with 
good selectivity for both PI3Kγ and δ. Infinity and Intellikine have an ongoing 
phase I trial with IPI-145 (Figure 2) and Rhizen Pharmaceuticals have 
recently announced the initiation of a phase I trial with novel compound 
RP6530 [18] which represent the only PI3Kδ/γ inhibitors currently in clinical 
development [10]. 
 
Evidence for a Role of PI3K in Autoimmune Pathology 
 
Rheumatoid arthritis 
RA is a chronic autoimmune disease, which predominantly causes 
inflammation in small joints of the hands and feet causing immobilization and 
disability. In RA, the structure of the synovium is transformed into a pannus-
like tissue, which invades cartilage and erodes bone. Strong granulocyte and 
lymphocyte recruitment causes the inflamed synovium to consist of multiple 
inflammatory cells, such as macrophages, neutrophils, and T and B cells. 
Hyperplasia of synovial lining cells occurs, which are predominantly fibroblast-
like synoviocytes [19] and damage to tissue is driven by aggressive 
inflammatory cytokine signaling in these joints. Given that PI3Kγ has a pivotal 
role in mediating leukocyte migration and activation as well as mast cell 
degranulation [10], it was predicted that blocking PI3Kγ may be an effective 
strategy to fight RA.  The collagen induced arthritis (CIA) model reflects the 
immunological components of the disease and constitutes an acute T-cell-
mediated autoimmune arthritis that focuses on the effector phase of arthritis. 
In this model, PI3Kγ null mice exhibited reduced paw swelling, synovial 
inflammation and cartilage erosion, while inhibition of PI3K decreased 
neutrophil infiltration as well as Th17 differentiation, a pro-inflammatory helper 
T cell type characterized by expression of the cytokine IL-17 [17,20]. 
 
The transgenic overexpression of human tumor necrosis factor (hTNF)α leads 
to a chronic inflammatory destructive polyarthritis similar to human RA and is 
sensitive to neutralizing anti-TNFα antibodies. Loss of PI3Kγ in human TNFα 
mice led to reduced arthritis compared to controls [21]. Interestingly, PI3Kγ 
deficiency does not alter the recruitment of inflammatory cells as observed in 
the CIA model of RA, but it significantly reduces cartilage damage through 
reduced expression of matrix metalloproteinases in fibroblasts and 
chondrocytes. PI3Kγ expression is significantly higher in the synovium of RA 
patients compared to synovium from osteoarthritis patients. Furthermore, 
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inhibition of PI3Kγ reduced TNFα-induced MMP production in fibroblasts 
isolated from human RA patients [21]. This study therefore, provides further 
mechanistic insights into PI3Kγ in RA that extends beyond its established role 
in immune cell migration. 
 
PI3Kδ mRNA and protein expression is also higher in RA than osteoarthritis 
synovium [22] and PI3Kδ mRNA can be induced in cultured synoviocytes by 
inflammatory cytokines. In a K/BxN-serum transfer model of arthritis, in which 
neutrophils and LTB4 participate in the effector phase of the inflammatory 
arthritis, selective inhibition of PI3Kδ diminishes joint erosion to a level 
comparable to inhibition of its PI3Kγ counterpart. Induction and progression of 
joint destruction was profoundly reduced in the absence of both PI3K isoforms 
and is consistent with both isoforms being required for LTB4-mediated 
neutrophil chemotaxis as described earlier [21]  
 
Important differences between PI3Kγ and PI3Kδ have been noted in the 
mechanisms underpinning joint destruction. For example, in a model of 
osteoclastogenesis, the PI3Kδ selective inhibitor IC-87114 significantly 
inhibited the generation of osteoclasts whereas selective inhibition of PI3Kγ 
with AS-605240 had no effect [23]. Taken together, these lines of evidence 
suggest that dual inhibition of PI3Kγ and PI3Kδ would be more therapeutically 
beneficial than targeting one isoform alone. 
 
Systemic Lupus Erythematous (SLE)  
SLE is a complex multisystem autoimmune disease characterised by the 
presence of autoreactive antibodies and chronic activation of the immune 
system. Typically, initial overproduction of memory CD4+ T lymphocytes leads 
to hyperactivity of polyclonal B lymphocytes and induces their rapid expansion 
and production of autoantibodies. The presence of anti-nuclear autoantibodies 
can lead to the formation of complexes that are retained in the kidney in half 
of all patients and lead to leukocyte infiltration, ultimately causing renal failure 
and glomerulonephritis [24]. Current therapies poorly control disease 
indicators, necessitating potent immunosuppression to achieve remission.  
 
Several lines of evidence suggest dysregulated PI3K-dependent signalling in 
mouse models of SLE.  For example, deletion of PI3Kγ in a mouse model 
reduced the survival of pathogenic memory CD4+ lymphocytes, which 
ultimately led to inhibition of glomerulonephritis and enhanced survival rate. 
Furthermore, treatment of these mice with PI3Kγ inhibitor AS-605240 also 
reduced autoantibody production and increased survival [25].  In addition, 
there is evidence that the PI3K/Akt/mTOR pathway is up-regulated in murine 
lupus nephritis [26].  Mice deficient in the src family kinase Lyn, show clinical, 
pathological and biochemical features of SLE and hyper-activation of PI3K 
signaling.  Inactivation of PI3Kδ was enough to halt disease in Lyn-deficient 
mice [27]. In this regard, increased PI3Kδ but not γ activity was observed in 
SLE patients which correlated with resistance of activated and memory T cells 
to activation induced cell death and increased number of memory T cells.  
This highlights an important role for PI3Kδ in SLE [28]. 
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Multiple sclerosis (MS) 
MS is an autoimmune disease whereby immune activation leads to 
destruction of  the myelin sheath surrounding nerve fibres  which impairs 
signals to and from the brain affecting muscle control, vision, balance and 
causing fatigure, loss of sensation or numbness. MS gets its name from the 
build-up of scar tissue (sclerosis) in the brain and/or spinal cord. Experimental 
autoimmune encephalomyelitis (EAE) is an induced method of autoimmune 
inflammation of the central nervous system (CNS) commonly used to model 
diseases such as MS in rodents. Considerable evidence now indicates that 
the T cell lineage most likely to be driving EAE pathogenesis are Th17 cells 
[29]. In a Th17-driven EAE model, the absence of PI3Kγ delayed progression 
of motor dysfunction and reduced pro-inflammatory chemokines as well as 
numbers of infiltrating immune cells in the meninges of PI3Kγ deficient mice 
[30]. Both genetic and pharmacological targeting of PI3Kγ indicated that it 
plays an important role in mediating leukocyte survival rather than leukocyte 
adhesion in this experimental model of MS.  
Another group has reported signaling through PI3Kδ is required for full and 
sustained pathology of EAE. Thus, in PI3Kδ-inactivated mice, T cell activation 
and function during EAE was markedly reduced and fewer T cells were 
observed in the CNS.  Reminiscent of observations made in the PI3Kγ 
deficient mice, there were significant increases in the proportion of T cells 
undergoing apoptosis at early stages of EAE in the absence of PI3Kδ activity. 
Furthermore, a profound defect in Th17 cellular responses during EAE was 
apparent in the absence of PI3Kδ activity. The PI3Kδ inhibitor, IC-87114, also 
had greater inhibitory effects on Th17 cell generation in vitro than it did on Th1 
cell generation. Taken together, these data indicate that both PI3Kγ and 
PI3Kδ can contribute to the pathogenesis of EAE, influencing cell survival, 
differentiation and migration mechanisms [31]. Thus, dual targeting of PI3Kγ 
and δ might be a therapeutic option for the treatment of EAE. 
 
Type 1 Diabetes 
Type 1 diabetes (T1D) is an autoimmune disease characterised by expansion 
and activation of T lymphocytes specific for components of pancreatic beta 
cells. Activated T lymphocytes infiltrate the islets of Langerhans and either kill 
beta cells or promote local inflammation of the pancreas, ultimately causing 
beta cell dysfunction and death [32].   Following promising early results in a 
number of animal disease models, the specific PI3Kγ inhibitor AS605240 has 
recently been tested in NOD mice to investigate its effect on T1D. This 
revealed that PI3Kγ is important in regulating the balance of T lymphocyte 
subsets during the pathogenesis of T1D. AS605240 suppressed autoreactive 
T lymphocytes and T lymphocyte infiltration into pancreatic islets whilst 
promoting regulatory T lymphocyte (Treg) expansion.  Furthermore, PI3Kγ 
inhibition prevented the development of diabetes in prediabetic NOD mice and 
reversed hyperglycemia in newly hyperglycemic NOD mice, possibly through 
expansion of the suppressive Treg lymphocyte subset [32]. This preclinical 
study offers an important indication of the potential successes of T 
lymphocyte targeted PI3Kγ inhibition therapy for patients with T1D. 
 
 8 
The PI3Kδ isoform of PI3K has prominent roles in B lymphocyte activation, 
proliferation and antigen presentation which are associated with initiating and 
maintaining destructive inflammatory processes.  For example, in a model of 
T1D, non-obese diabetic (NOD) mice that lack B cells do not develop 
spontaneous autoimmune diabetes seen in wild-type NOD mice [33].   In the 
NOD mouse model, the PI3Kδ inhibitor IC87114 impaired infiltration of 
inflammatory cells into the pancreatic islets. IC87114 also prevented the in 
vitro activation of diabetogenic T lymphocytes by NOD B cells. Furthermore, 
IC87114 delayed the onset, reduced severity and prevented progression of 
autoimmune diabetes in this mouse model [34]. Thus, for the roles of both T- 
and B-lymphocytes in T1D, the PI3K pathway is a key driver of lymphocyte 
activation and expansion, making it an attractive target for therapeutic 
intervention. 
 
Conclusions: 
The and  isoforms of PI3K have important non-redundant roles in multiple 
cells of the immune system. Consequently alterations of the PI3K signaling 
pathway can lead to inflammatory and autoimmune disorders as well as 
leukemia. This, together with growing appreciation of the crystal structure of 
the catalytic isoforms which help define the structure-activity rules for 
obtaining selectivity, will spur the continued design and development of 
improved PI3K inhibitors that are more selective, potent and with negligible 
off-target effects. These offer opportunities to manipulate the PI3K signaling 
network in immune cells nor only for autoimmune diseases but also for 
inflammatory conditions and transplantation as well as cancer. The latter 
could include targeting non-leukemic cancers, given the up-regulation of 
PI3Kγ and PI3Kδ in some forms of non-immune cell cancers, though it might 
be difficult to avoid effects on the immune system which might impair the 
endogenous anti-tumor response.  
 
While there is optimism for targeting PI3K in autoimmune disease, there still 
remains key questions surrounding  this therapeutic approach (Box 1). 
Furthermore, PI3K signalling comprises many areas of functional redundancy 
and plasticity, so targeted therapies are unlikely to have an effect across the 
range of conditions in which PI3K is involved. Second, targeting of PI3K 
catalytic isoforms does not necessarily silence PI3K signaling since Akt can 
be activated independently of the recognized PI3K/PDK1/mTORC2/PH 
domain-mediated mechanisms [35]. Furthermore, worryingly, the emergence 
of resistance mechanisms to PI3K targeted therapy has recently been 
reported [36].  Nevertheless, the emerging success of PI3K inhibitors in 
clinical trials for cancer and malignancies there remains hope that effective 
candidates will progress into trials for autoimmune diseases. The intense 
interest around PI3K isoforms, shared by immunologists, biomedical 
researchers, and pharmacologists, should ultimately yield badly needed 
therapies for major autoimmune conditions.  
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Figure Legends: 
 
Figure 1: a) Schematic of PI3K signalling.  Class I PI3K enzymes 
phosphorylate the D3 position on the inositol ring of phosphatidylinositol 4,5-
bisphosphate [PI(4,5)P2] to generate PI(3,4,5)P3 which is located in the 
plasma membrane and acts as a docking site to recruit and activate pleckstrin 
homology (PH) domain containing proteins  that in turn regulate downstream 
effector proteins.  Numerous PH-domain containing proteins are activated by 
PI3K signaling, these include protein kinase B/Akt and 3’-phosphoinositide-
dependent kinase-1 (PDK1), a range of adaptor/scaffolding proteins as well 
as guanine nucleotide exchange factors (GEFs) which regulate GTPases and 
hence cell motility and intracellular trafficking.  PI3K signaling activity is tightly 
regulated by at least two lipid phosphatases: SH2-domain containing inositol-
5-phosphatase (SHIP) and phosphatase and tensin homolog (PTEN). SHIP 
de-phosphorylates PI(3,4,5)P3 at the D5 position of the inositol ring to create 
phosphatidylinositol 3,4-bisphosphate [PI(3,4)P2], whereas PTEN de-
phosphorylates the D3 position to create PI(4,5)P2 . b) Structural domains 
of PI3K Class I enzymes. Class IA and IB share core domain structure of 
single Ras binding, C2, helical and catalytic domains. Class IA have a p85 
regulatory subunit-binding (p110α/β/δ) domains, whilst Class IB enzymes 
have p101/p84/p87-binding (p110γ) domains.  
 
Figure 2: Individual and combined roles of Class I PI3K γ and δ isoforms 
in autoimmune disease. Here the relative involvement and selective 
inhibitors of PI3K isoforms in autoimmune disease are summarized.   
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Box 1. Current key questions regarding the use of PI3K inhibitors in 
autoimmune and inflammatory disease 
1. How reflective are rodent models of the actual human disease with 
regard to the role of PI3Ks? 
2. Will selective small molecule inhibitors of PI3Ks gain the same benefit 
as gene ablation strategies (either by gene deletion or knock-in 
mutation)? 
3. Will isoform selective inhibitors avoid the toxicity problems associated 
with LY294002  
4. Do isoform selective inhibitors retain sufficient efficacy to alter disease 
progression? 
5. Are any side effects of PI3K inhibitors (isoform selective, isoform 
preference, pan-isoform and multi-kinase) commensurate with the 
disease being treated? 
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